Literature DB >> 15515019

Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas.

Ester Martín-Villar1, Francisco G Scholl, Carlos Gamallo, Maria M Yurrita, Mario Muñoz-Guerra, Jesús Cruces, Miguel Quintanilla.   

Abstract

We report the full cDNA sequence encoding the human homologue of murine PA2.26 (T1alpha-2, podoplanin), a small mucin-type transmembrane glycoprotein originally identified as a cell-surface antigen induced in keratinocytes during mouse skin carcinogenesis. The human PA2.26 gene is expressed as 2 transcripts of 0.9 and 2.7 kb in several normal tissues, such as the placenta, skeletal muscle, heart and lung. Using a specific polyclonal antibody raised against a synthetic peptide of the protein ectodomain, PA2.26 was immunohistochemically detected in about 25% (15/61) of human early oral squamous cell carcinomas. PA2.26 distribution in the tumours was heterogeneous and often restricted to the invasive front. Double immunofluorescence and confocal microscopy analysis showed that PA2.26 colocalized with the membrane cytoskeleton linker ezrin at the surface of tumour cells and that its presence in vivo was associated with downregulation of membrane E-cadherin protein expression. Ectopic expression of human PA2.26 in HeLa carcinoma cells and immortalized HaCaT keratinocytes promoted a redistribution of ezrin to the cell edges, the formation of cell-surface protrusions and reduced Ca(2+)-dependent cell-cell adhesiveness. These results point to PA2.26 as a novel biomarker for oral squamous cell carcinomas that might be involved in migration/invasion. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15515019     DOI: 10.1002/ijc.20656

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  97 in total

1.  Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival.

Authors:  Juan Carlos de Vicente; Tania Rodríguez Santamarta; Juan Pablo Rodrigo; Juana María García-Pedrero; Eva Allonca; Verónica Blanco-Lorenzo
Journal:  Virchows Arch       Date:  2015-03-01       Impact factor: 4.064

2.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Authors:  Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

3.  Genome-wide two-locus epistasis scans in prostate cancer using two European populations.

Authors:  Sha Tao; Junjie Feng; Timothy Webster; Guangfu Jin; Fang-Chi Hsu; Shyh-Huei Chen; Seong-Tae Kim; Zhong Wang; Zheng Zhang; Siqun L Zheng; William B Isaacs; Jianfeng Xu; Jielin Sun
Journal:  Hum Genet       Date:  2012-02-26       Impact factor: 4.132

4.  Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.

Authors:  Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina; Tohru Ikeda
Journal:  Pathol Oncol Res       Date:  2013-11-28       Impact factor: 3.201

5.  Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility.

Authors:  Harini Krishnan; Jhon A Ochoa-Alvarez; Yongquan Shen; Evan Nevel; Meenakshi Lakshminarayanan; Mary C Williams; Maria I Ramirez; W Todd Miller; Gary S Goldberg
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

6.  Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer.

Authors:  Agnes Assao; Suely Nonogaki; José Roberto Pereira Lauris; André Lopes Carvalho; Clóvis Antônio Lopes Pinto; Fernando Augusto Soares; Luiz Paulo Kowalski; Denise Tostes Oliveira
Journal:  Clin Oral Investig       Date:  2016-09-14       Impact factor: 3.573

7.  Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas.

Authors:  Juan P Rodrigo; Dario García-Carracedo; María V González; Gonzalo Mancebo; Manuel F Fresno; Juana García-Pedrero
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

8.  Immunohistochemical examination on the distribution of cells expressed lymphatic endothelial marker podoplanin and LYVE-1 in the mouse tongue tissue.

Authors:  Yuya Noda; Ikuko Amano; Minoru Hata; Hiroshi Kojima; Yoshihiko Sawa
Journal:  Acta Histochem Cytochem       Date:  2010-04-07       Impact factor: 1.938

9.  Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells.

Authors:  Hanako Suzuki; Mitsuho Onimaru; Yoshikazu Yonemitsu; Yoshihiko Maehara; Seiji Nakamura; Katsuo Sueishi
Journal:  Mol Cancer       Date:  2010-10-31       Impact factor: 27.401

Review 10.  Podoplanin--a novel marker in oral carcinogenesis.

Authors:  Niharika Swain; Shwetha V Kumar; Samapika Routray; Jigna Pathak; Shilpa Patel
Journal:  Tumour Biol       Date:  2014-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.